ORPHA:126
Blepharophimosis-ptosis-epicanthus inversus syndrome
Also known as: BPES
Publications
4,930
Trials
0
Interventional, condition-specific
Researchers
1,091
Distinct authors in sample
Gene link
FOXL2
Definitive
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare ophthalmic disorder characterized by blepharophimosis, ptosis, epicanthus inversus, and telecanthus, that can appear associated with (type 1) or without primary ovarian insufficiency (POI; type 2).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007201
- MeSH:C562419
- OMIM:110100
- UMLS:C0220663
Additional Mondo synonyms (8)
Blepharophimosis, Ptosis, Epicanthus Inversus Syndrome · blepharophimosis types 1 and 2 · blepharophimosis, epicanthus inversus, and ptosis, type 1 · blepharophimosis, epicanthus inversus, and ptosis, type 2 · blepharophimosis, ptosis, and epicanthus inversus · blepharophimosis, ptosis, and epicanthus inversus syndrome · blepharophimosis, ptosis, epicanthus inversus syndrome · blepharophimosis-epicanthus inversus-ptosis syndrome
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No matched interventional trial, but a gene association and an animal model are on record — often described as translation-ready / stalled at the clinical step.
- Gene identifiedPresent
Definitive — FOXL2
- LiteraturePresent
4,930 matched papers (3,449 in last 10 years) Source
- Phenotype characterisedPresent
33 HPO annotations (e.g. Amenorrhea; Irregular menstruation; Epicanthus inversus) Source
- Animal modelPresent
3 genotype models (Mus musculus) Source
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (FOXL2).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
33
Associated phenotypes · MONDO:0007201
- Amenorrhea
- Irregular menstruation
- Epicanthus inversus
- Wide nasal bridge
- Narrow palpebral fissure
Showing 5 of 33 — open Monarch for the full list.
Animal models (Monarch / Alliance)
3
Model associations linked to this Mondo ID
- Foxl2tm1Gpil/Foxl2tm1Gpil [background:] either: 129S6/SvEvTac or (involves: 129S6/SvEvTac * C57BL/6J) or (involves: 129S6/SvEvTac * NIHS-BC)·MGI:3044667·Mus musculus
- E330023G01RikTn(pb-Act-RFP)1.1Zhu/E330023G01RikTn(pb-Act-RFP)1.1Zhu [background:] involves: FVB/N·MGI:5907679·Mus musculus
- Foxl2tm1Tre/Foxl2tm1Tre [background:] involves: 129P2/OlaHsd * Black Swiss * CD-1·MGI:3029674·Mus musculus
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
4,930
4,930 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
4,930 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,449 in the last 10 years · low confidence
Phrase hits: 592 · MeSH hits: 0
Who's working on it?
1,091
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang T8 papers · 2024
The 3rd Department, Plastic Surgery Hospital of the Chinese Academy of Medical Sciences, Peking Union Medical College, Badachu Road, Shijingshan District, No. 33, Beijing, 100041, China. tailing.cn.wang@gmail.com.
Papers in Europe PMC - 02Li H7 papers · 2025
Eye Center, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Zhejiang Provincial Key Laboratory of Ophthalmology, Zhejiang Provincial Clinical Research Center for Eye Diseases, Zhejiang Provincial Engineering Institute on Eye Diseases, Hangzhou, China.
Papers in Europe PMC - 03Li J7 papers · 2024
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou, China.
Papers in Europe PMC - 04De Baere E6 papers · 2026
Center for Medical Genetics, Ghent University, Ghent University Hospital, Ghent, Belgium.
Papers in Europe PMC - 05Verdin H6 papers · 2026
Center for Medical Genetics, Ghent University, Ghent University Hospital, Ghent, Belgium.
Papers in Europe PMC - 06Wang J6 papers · 2024
The 3rd Department, Plastic Surgery Hospital of the Chinese Academy of Medical Sciences, Peking Union Medical College, Badachu Road, Shijingshan District, No. 33, Beijing, 100041, China.
Papers in Europe PMC - 07Zhou Y6 papers · 2025
College of Animal Science and Technology, Jilin Agricultural University, Changchun, 130118, China.
Papers in Europe PMC - 08Ge S5 papers · 2022
Department of Ophthalmology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
Papers in Europe PMC - 09Jia R5 papers · 2019
Department of Ophthalmology, Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P.R. China.
Papers in Europe PMC - 10Wang Y5 papers · 2025
National MOE Key Laboratory of Gene Resource Utilization for Important Genetic Disease, Anhui Key Laboratory of Genetic Research, Hefei, China. aydesm-1@163.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-29
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- ctis·2024-516865-35-01·Authorised·Head-to-Head Comparison of the Efficacy and Safety of All Commercially Available Botulinum Neurotoxin Type A Products for the Treatment of Glabellar Rhytides: A Multicenter, Triple-Blind, Randomized Controlled Trial
skipped — LLM skipped (--skip-llm)
- ctis·2023-506656-24-00·Authorised, ongoing·Immediate corticosteroid therapy and rituximab to prevent generalization in ocular myasthenia gravis: a PROBE-type multicenter, open-label, randomized controlled trial
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Blepharophimosis-ptosis-epicanthus inversus syndrome — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("Blepharophimosis-ptosis-epicanthus inversus syndrome" OR "Blepharophimosis, Ptosis, Epicanthus Inversus Syndrome" OR "blepharophimosis types 1 and 2" OR "blepharophimosis, epicanthus inversus, and ptosis, type 1" OR "blepharophimosis, epicanthus inversus, and ptosis, type 2" OR "blepharophimosis, ptosis, and epicanthus inversus" OR "blepharophimosis, ptosis, and epicanthus inversus syndrome" OR "blepharophimosis-epicanthus inversus-ptosis syndrome") OR ("FOXL2" OR "FOXL2 syndrome" OR "FOXL2-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Blepharophimosis-ptosis-epicanthus inversus syndrome" OR "Blepharophimosis, Ptosis, Epicanthus Inversus Syndrome" OR "blepharophimosis types 1 and 2" OR "blepharophimosis, epicanthus inversus, and ptosis, type 1" OR "blepharophimosis, epicanthus inversus, and ptosis, type 2" OR "blepharophimosis, ptosis, and epicanthus inversus" OR "blepharophimosis, ptosis, and epicanthus inversus syndrome" OR "blepharophimosis-epicanthus inversus-ptosis syndrome"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: BPES
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (4930) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-26T12:32:00.193Z
